Share on

North America Gene Therapy Market Research Report - Segmented By Vector Type, Application and Country (The United States, Canada and Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 11789
Pages: 100
Formats: report pdf report excel report power bi report ppt

North America Gene Therapy Market Size (2023 to 2028)

The size of the gene therapy market in the North American region is estimated to grow at a CAGR of 28.84% during the forecast period.

The growing adoption of gene therapy across North American countries is one of the major factors uplifting the gene therapy market in this region. Owing to the increasing number of genetic disorders, with the less available or high cost of medicine, the adoption of gene therapy has increased. Healthcare providers use gene therapy to modify the gene to prevent or reduce the disease, and this therapy is widely used to treat cancer patients. New genes are injected into the body where the cancer growth or near the surrounding tissue to make the cancer cell die in the gene therapy for cancer treatment. Gene therapy is also being used to create recombinant cancer vaccines, which help to cure cancer by increasing the immune system in the patient.

The growing population suffering from neurodegenerative diseases is another factor propelling market growth. Alzheimer's and Parkinson's disease are the most common neurodegenerative diseases. In the U.S. nearly, 6.2 million people suffer from these diseases, according to the Alzheimer's Disease Association in 2022. Therefore, increasing awareness about gene therapy and increasing healthcare expenditure by the people drives the market forward in the North American region.

Growing R&D activities around gene therapy are another factor fuelling the market growth. Gene therapy is used in the medical treatment of hematological, ocular, and several cancers. Additionally, key players are manufacturing advanced gene therapy products and increasing advanced technologies for the procedure, which boosts the market forward.

However, high costs associated with gene therapy, lack of regulatory approvals for the products, complex treatment procedures, lack of skilled professionals, and lack of awareness among people are majorly hampering the gene therapy market in North America. In addition, long durations associated with the drug approval process are another notable factor restricting the market growth. Clinical trials for drug manufacturing take more than one year to slow the market growth.

This research report on the North American gene therapy market has been segmented & sub-segmented into the following categories:

 By Vector Type:

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno-associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

By Application:

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Country:

  • The U.S.
  • Canada
  • Rest of North America

Geographically, the North American region is one of the leading regions for gene therapy in the worldwide market. The U.S. Food and Drug Administration (FDA) started approving gene therapy products for sale in the United States. Some of the recent development in gene therapy drugs that the FDA approved is Leber congenital amaurosis for an eye disorder, melanoma, and genetic muscle condition. Cystic fibrosis (C.F.) is a common genetic disease in the United States. Nearly 30,000 people in the United States suffer from C.F. Researchers at the University of Washington's Genome Center and Pathogenesis Corporation has done clinal genetic trials for the Pseudomonas aeruginosa bacterium. This bacterium is the reason for chronic and fatal lung infections for people. The market has grown during the forecast period by increasing all these types of clinical tails and research.

The U.S. market led the North American region in 2022. The growing number of thalassemia cases in the U.S. is one of the major factors promoting market growth. With early detection of thalassemia and using gene therapy, the severity of the disease can be reduced. The U.S. government conducted a program for genetic counseling to prevent new cases. As a result, nearly an 8 % increase in cases of thalassemia over the last five decades. In addition, increasing awareness programs by the U.S. government to promote the usage of gene therapy for thalassemia patients is further propelling the market growth in the U.S.

On the other hand, the Canadian market is anticipated to record a healthy CAGR during the forecast period. In Canada, Gene therapy must be approved by Health Canada's Biologics and Genetic Therapies Directorate, which will monitor all the clinical trials related to gene therapy. BGTD also checks the risk rate of using the drug before it is sold. In addition, health Canada certifies the safety testing of the drug in Canada. Increasing funding by the government for drug manufacturing also drives the market forward.

KEY MARKET PLAYERS:

A few of the promising companies operating in the North American gene therapy market profiled in this report are Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute, Sibiono Genetech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Uniqure N.V., Gensight Biologics S.A., Celgene Corporation, Cellectis, Sangamo Therapeutics, Mustang Bio, Applied Genetic Technologies Corporation and Poseida Therapeutics, Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample